Last reviewed · How we verify
Placebo for E2/NETA
This is a placebo control arm with no active pharmacological mechanism.
This is a placebo control arm with no active pharmacological mechanism. Used for Control arm in phase 3 trial for estradiol/norethindrone acetate (E2/NETA) hormone replacement therapy.
At a glance
| Generic name | Placebo for E2/NETA |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Therapeutic area | Women's Health / Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (estradiol/norethindrone acetate combination). It contains no active ingredients and serves as a baseline comparator to demonstrate that any observed clinical benefit is due to the active hormone therapy rather than non-specific effects.
Approved indications
- Control arm in phase 3 trial for estradiol/norethindrone acetate (E2/NETA) hormone replacement therapy
Common side effects
Key clinical trials
- Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (PHASE3)
- Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6) (PHASE3)
- Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (PHASE3)
- Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain. (PHASE3)
- A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain (PHASE3)
- A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain (PHASE3)
- Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PHASE3)
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for E2/NETA CI brief — competitive landscape report
- Placebo for E2/NETA updates RSS · CI watch RSS
- AbbVie portfolio CI